Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
08
05
2019
accepted:
29
07
2019
pubmed:
20
8
2019
medline:
2
6
2020
entrez:
18
8
2019
Statut:
ppublish
Résumé
Biologicals introduced a major shift in the treatment of patients suffering from inflammatory bowel diseases. Despite providing a tight disease control for many patients, a considerable proportion of patients will fail to respond favorably to treatment or will lose response over time. Therapeutic drug monitoring emerged as a valuable tool to guide clinical decision making as serum drug concentrations have been linked to outcomes. Focusing on mucosal healing as the ultimate treatment goal, different drug concentration thresholds to achieve this outcome have been identified in the literature and are summarized in this review. For therapeutic drug monitoring to be successful in guiding clinical decision making, the used assay, the sampling time point, and the outcome that is aimed for should be taken into account when interpreting drug concentration thresholds. Awareness of these essential aspects among clinicians will improve the implementation of therapeutic drug monitoring and aid in making an evidence-based decision.
Identifiants
pubmed: 31420861
doi: 10.1002/cpt.1609
pmc: PMC6858034
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
945-954Informations de copyright
© 2019 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Gastroenterology. 2014 Dec;147(6):1296-1307.e5
pubmed: 25173754
Ther Drug Monit. 2017 Aug;39(4):344-349
pubmed: 28328760
Inflamm Bowel Dis. 2014 Dec;20(12):2247-59
pubmed: 25358062
J Invest Dermatol. 2019 Oct;139(10):2232-2235.e1
pubmed: 31067484
Gastroenterology. 2018 May;154(6):1660-1671
pubmed: 29409871
Gastroenterology. 2011 May;140(6):1785-94
pubmed: 21530745
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8
pubmed: 29704680
J Crohns Colitis. 2019 Sep 27;13(10):1248-1256
pubmed: 30820530
Clin Chem Lab Med. 2015 Oct;53(11):e297-9
pubmed: 25945722
Gut. 2010 Jan;59(1):49-54
pubmed: 19651627
Clin Gastroenterol Hepatol. 2016 Apr;14(4):543-9
pubmed: 26681486
J Crohns Colitis. 2017 Aug 1;11(8):921-929
pubmed: 28333288
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1814-1821.e1
pubmed: 30613004
Dig Dis Sci. 2019 Jun;64(6):1651-1659
pubmed: 30835029
Clin Gastroenterol Hepatol. 2006 Oct;4(10):1248-54
pubmed: 16931170
J Crohns Colitis. 2017 Jan;11(1):35-46
pubmed: 27440869
Clin Transl Gastroenterol. 2016 Jan 07;7:e135
pubmed: 26741065
Inflamm Bowel Dis. 2016 Feb;22(2):409-15
pubmed: 26752470
Clin Gastroenterol Hepatol. 2014 Mar;12(3):423-31.e1
pubmed: 24184736
Clin Pharmacokinet. 2018 Sep;57(9):1075-1106
pubmed: 29512050
Ther Drug Monit. 2017 Aug;39(4):316-321
pubmed: 28570370
Aliment Pharmacol Ther. 2011 May;33(9):987-95
pubmed: 21366636
Clin Gastroenterol Hepatol. 2014 Jan;12(1):80-84.e2
pubmed: 23891927
Actas Dermosifiliogr. 2013 Jul-Aug;104(6):471-9
pubmed: 23622932
J Crohns Colitis. 2019 Jul 25;13(7):864-872
pubmed: 30715258
Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2
pubmed: 29935327
Gastroenterology. 2008 Jun;134(7):1861-8
pubmed: 18440315
J Pharm Biomed Anal. 2016 Jun 5;125:62-7
pubmed: 27003121
Aliment Pharmacol Ther. 2012 Oct;36(8):765-71
pubmed: 22928581
Clin Immunol. 2019 Sep;206:9-14
pubmed: 29545207
Clin Gastroenterol Hepatol. 2017 Sep;15(9):1427-1434.e2
pubmed: 28365485
J Crohns Colitis. 2016 May;10(5):575-81
pubmed: 26738756
Clin Pharmacol. 2017 Oct 03;9:101-111
pubmed: 29042821
Inflamm Bowel Dis. 2016 Aug;22(8):1859-69
pubmed: 27206015
Aliment Pharmacol Ther. 2018 Apr;47(7):906-912
pubmed: 29384209
J Crohns Colitis. 2019 Feb 1;13(2):172-181
pubmed: 30285104
Clin Gastroenterol Hepatol. 2016 Feb;14(2):251-8.e1-2
pubmed: 26545802
Clin Gastroenterol Hepatol. 2016 Apr;14(4):550-557.e2
pubmed: 26538204
Aliment Pharmacol Ther. 2018 Jan;47(2):229-237
pubmed: 29159893
Br J Clin Pharmacol. 2019 Apr;85(4):782-795
pubmed: 30634202
J Crohns Colitis. 2017 Jan;11(1):53-59
pubmed: 27402915
Eur J Gastroenterol Hepatol. 2019 Apr;31(4):478-485
pubmed: 30672828
Dig Liver Dis. 2013 Dec;45(12):969-77
pubmed: 23932331
Autoimmun Rev. 2013 May;12(7):703-8
pubmed: 23207283
Ther Drug Monit. 2019 Aug;41(4):459-466
pubmed: 30817702
J Crohns Colitis. 2016 May;10(5):510-5
pubmed: 26783345
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S39-50
pubmed: 25707962
Clin Transl Gastroenterol. 2016 Dec 8;7(12):e206
pubmed: 27929524
Gastroenterol Hepatol (N Y). 2013 Aug;9(8 Suppl 4):1-16
pubmed: 24872794
Inflamm Bowel Dis. 2019 Feb 21;25(3):580-586
pubmed: 30165638
Gut. 2012 Nov;61(11):1619-35
pubmed: 22842618
Expert Opin Biol Ther. 2014 Jan;14(1):75-101
pubmed: 24206084
AAPS J. 2018 Dec 18;21(1):10
pubmed: 30564993
Gut. 2016 Feb;65(2):249-55
pubmed: 25670812
Aliment Pharmacol Ther. 2018 Apr;47(7):896-905
pubmed: 29430672
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):15-29
pubmed: 19949430
Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):243-55
pubmed: 24393836